Syndax Pharmaceuticals (SNDX) Other financing activities (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Other financing activities of $7.5 million for Q1 2026, up 1268.81% year-over-year from $545000.0 in Q1 2025, and up 241.07% quarter-over-quarter from -$5.3 million in Q4 2025.
Syndax Pharmaceuticals (SNDX) Other financing activities (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Other financing activities history runs 12 years deep, the most recent figure standing at $7.5 million for Q1 2026.
- In Q1 2026, Other financing activities rose 1268.81% year-over-year to $7.5 million; the TTM figure through Mar 2026 stood at $8.5 million (up 333.26% YoY), while the FY2025 annual figure was $1.5 million, down 10.32% from the prior year.
- Other financing activities for Q1 2026 stood at $7.5 million, up from -$5.3 million in the prior quarter.
- The five-year high for Other financing activities was $7.5 million in Q1 2026, with the low at -$5.3 million in Q4 2025.
- The 5-year median for Other financing activities is $545000.0 (2025), against an average of $1.6 million.
- The sharpest annual moves came in 2022 and 2025: Other financing activities surged 7337.37% in 2022, then plunged 934.07% in 2025.
- Syndax Pharmaceuticals' Other financing activities stood at $1.4 million in 2022, then tumbled by 92.21% to $112000.0 in 2023, then surged by 466.07% to $634000.0 in 2024, then slumped by 934.07% to -$5.3 million in 2025, then soared by 241.07% to $7.5 million in 2026.
- Business Quant data shows SNDX's Other financing activities at $7.5 million in Q1 2026, -$5.3 million in Q4 2025, and $6.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Syndax Pharmaceuticals | 1.77 Bn | 1.22 Bn | 60.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.76 Mn |
| Jun 30, 2026 | 8.76 Mn |
| Mar 31, 2026 | 7.46 Mn |
| Mar 31, 2026 | 7.46 Mn |
| Dec 31, 2025 | -5.29 Mn |
| Dec 31, 2025 | -5.29 Mn |
| Sep 30, 2025 | 6.36 Mn |
| Sep 30, 2025 | 6.36 Mn |
| Jun 30, 2025 | -77,000.00 |
| Jun 30, 2025 | -77,000.00 |
| Mar 31, 2025 | 545,000.00 |
| Mar 31, 2025 | 545,000.00 |
| Dec 31, 2024 | 634,000.00 |
| Dec 31, 2024 | 634,000.00 |
| Sep 30, 2024 | 535,000.00 |
| Sep 30, 2024 | 535,000.00 |
| Jun 30, 2024 | 237,000.00 |
| Jun 30, 2024 | 237,000.00 |
| Mar 31, 2024 | 309,000.00 |
| Mar 31, 2024 | 309,000.00 |